TapewireFind a company

person · Reporting owner

COHEN ALAIN J

Disclosed activity across 1 company

Tapewire entity
128332
SEC CIK
0001132946

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
C4 Therapeutics, Inc.CCCC · Entity 5503DirectorApril 04, 2022April 05, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

C4 Therapeutics, Inc.

Report date April 04, 2022 · Filed April 05, 2022

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect928 Reported balance After 2022-04-04 transaction · row 1
1 source row

Row 1 · 2022-04-04 · Grant · Acquired 388 · Balance 928

F1: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.

F2: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on April 4, 2022.

Common StockSEC Table I · non-derivativeIndirectBy Alain J. Cohen Revocable Trust1,804,324 Reported balance Holding disclosure · report date 2022-04-04 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 1,804,324

F3: Shares held by the Reporting Person as trustee of the Alain J. Cohen Revocable Trust.

Filing footnotes · ownership attribution and instrument terms

F1: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.

F2: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on April 4, 2022.

F3: Shares held by the Reporting Person as trustee of the Alain J. Cohen Revocable Trust.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
April 04, 2022 Filed Apr 5, 2022 16:26 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 GrantCommon Stock 388 $26.46 $10,266.48
Disclosure

SEC source: 0001209191-22-023018 · doc4.xml · nonDerivative · entry 1

COHEN ALAIN J · CIK 0001132946 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 928

F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.

F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on April 4, 2022.

Read SEC document
January 04, 2022 Filed Jan 18, 2022 16:30 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 GrantCommon Stock 318 $31.58 $10,042.44
Disclosure

SEC source: 0001209191-22-003501 · doc4.xml · nonDerivative · entry 1

COHEN ALAIN J · CIK 0001132946 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 540

F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.

F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on January 4, 2022.

Read SEC document
October 04, 2021 Filed Oct 5, 2021 16:54 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 GrantCommon Stock 222 $44.99 $9,987.78
Disclosure

SEC source: 0001209191-21-059516 · doc4.xml · nonDerivative · entry 1

COHEN ALAIN J · CIK 0001132946 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 222

F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.

F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on October 4, 2021.

F3 · balance_after: This amount has been adjusted to reflect 517 shares previously transferred from the Reporting Person to the Alain J. Cohen Revocable Trust.

Read SEC document
July 02, 2021 Filed Jul 7, 2021 16:30 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 GrantCommon Stock 251 $39.72 $9,969.72
Disclosure

SEC source: 0001209191-21-045805 · doc4.xml · nonDerivative · entry 1

COHEN ALAIN J · CIK 0001132946 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 517

F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.

F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on July 2, 2021.

F3 · balance_after: This amount has been adjusted to reflect 61,877 shares previously transferred from the Reporting Person to the Alain J. Cohen Revocable Trust.

Read SEC document
June 15, 2021 Filed Jun 17, 2021 16:15 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 GrantStock Option (Right to Buy) · Derivative 23,500 $0.00 Strike: $37.66 $0.00
Disclosure

SEC source: 0001209191-21-041424 · doc4.xml · derivative · entry 1

COHEN ALAIN J · CIK 0001132946 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,500

Underlying: Common Stock · 23,500 shares

Expires 2031-06-14

F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 15, 2022 and (ii) the next annual meeting of the Issuer's stockholders.

Read SEC document
June 14, 2021 Filed Jun 14, 2021 17:16 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 OtherCommon Stock 22,598 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-040277 · doc4.xml · nonDerivative · entry 2

COHEN ALAIN J · CIK 0001132946 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,741,930

F1 · kind: Represents the receipt of shares by the Reporting Person pursuant to pro rata distributions-in-kind, without consideration, of shares of the company's common stock effected on June 14, 2021 by Cobro Ventures Opportunity Fund, L.P. ("Cobro Ventures") to the partners of Cobro Ventures and by its general partner, Cobro Ventures Fund GP, LLC. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.

F2 · ownership.nature: Shares held by the Reporting Person as trustee of the Alain J. Cohen Revocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Read SEC document
June 14, 2021 Filed Jun 14, 2021 17:16 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 OtherCommon Stock 61,877 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-040277 · doc4.xml · nonDerivative · entry 1

COHEN ALAIN J · CIK 0001132946 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,143

F1 · kind: Represents the receipt of shares by the Reporting Person pursuant to pro rata distributions-in-kind, without consideration, of shares of the company's common stock effected on June 14, 2021 by Cobro Ventures Opportunity Fund, L.P. ("Cobro Ventures") to the partners of Cobro Ventures and by its general partner, Cobro Ventures Fund GP, LLC. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.

Read SEC document
April 05, 2021 Filed Apr 6, 2021 16:30 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 GrantCommon Stock 266 $37.51 $9,977.66
Disclosure

SEC source: 0001209191-21-025662 · doc4.xml · nonDerivative · entry 1

COHEN ALAIN J · CIK 0001132946 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 266

F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.

F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on April 5, 2021.

Read SEC document
October 06, 2020 Filed Oct 6, 2020 21:24 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 ConversionSeries B Preferred Stock · Derivative 20,952,403 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-027690 · doc4.xml · derivative · entry 6

COHEN ALAIN J · CIK 0001132946 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Cobro Ventures Opportunity Fund, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 2,484,425 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F3 · ownership.nature: Shares held by Cobro Ventures Opportunity Fund, L.P. ("Cobro Ventures"). The Reporting Person serves as a manager of Cobro Opportunity Fund GP, LLC, the general partner of Cobro Ventures, and may be deemed to exercise voting and investment power over the shares held by Cobro Ventures. The Reporting Person disclaims beneficial ownership of the shares held by Cobro Ventures except to the extent of his pecuniary interest therein.

Read SEC document
October 06, 2020 Filed Oct 6, 2020 21:24 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 ConversionSeries A Preferred Stock · Derivative 12,500,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-027690 · doc4.xml · derivative · entry 5

COHEN ALAIN J · CIK 0001132946 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,482,183 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F2 · ownership.nature: Shares held by the Reporting Person as trustee of the Alain J. Cohen Revocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Read SEC document
October 06, 2020 Filed Oct 6, 2020 21:24 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 ConversionSeries Seed Preferred Stock · Derivative 2,000,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-027690 · doc4.xml · derivative · entry 4

COHEN ALAIN J · CIK 0001132946 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 237,149 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F2 · ownership.nature: Shares held by the Reporting Person as trustee of the Alain J. Cohen Revocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Read SEC document
October 06, 2020 Filed Oct 6, 2020 21:24 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 ConversionCommon Stock 2,484,425 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-027690 · doc4.xml · nonDerivative · entry 3

COHEN ALAIN J · CIK 0001132946 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Cobro Ventures Opportunity Fund, L.P.

Disclosed balance after: 2,484,425

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F3 · ownership.nature: Shares held by Cobro Ventures Opportunity Fund, L.P. ("Cobro Ventures"). The Reporting Person serves as a manager of Cobro Opportunity Fund GP, LLC, the general partner of Cobro Ventures, and may be deemed to exercise voting and investment power over the shares held by Cobro Ventures. The Reporting Person disclaims beneficial ownership of the shares held by Cobro Ventures except to the extent of his pecuniary interest therein.

Read SEC document
October 06, 2020 Filed Oct 6, 2020 21:24 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 ConversionCommon Stock 1,482,183 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-027690 · doc4.xml · nonDerivative · entry 2

COHEN ALAIN J · CIK 0001132946 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,719,332

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F2 · ownership.nature: Shares held by the Reporting Person as trustee of the Alain J. Cohen Revocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Read SEC document
October 06, 2020 Filed Oct 6, 2020 21:24 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 ConversionCommon Stock 237,149 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-027690 · doc4.xml · nonDerivative · entry 1

COHEN ALAIN J · CIK 0001132946 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 237,149

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F2 · ownership.nature: Shares held by the Reporting Person as trustee of the Alain J. Cohen Revocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Read SEC document
October 01, 2020 Filed Oct 5, 2020 21:00 UTC C4 Therapeutics, Inc. CCCC · Entity 5503 GrantStock Option (Right to Buy) · Derivative 17,786 $0.00 Strike: $19.00 $0.00
Disclosure

SEC source: 0000899243-20-027444 · doc4.xml · derivative · entry 1

COHEN ALAIN J · CIK 0001132946 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,786

Underlying: Common Stock · 17,786 shares

Expires 2030-09-30

F1 · derivative.exercise_date: This option shall vest and become exercisable upon the earlier to occur of (i) October 1, 2021, and (ii) the next annual meeting of the Issuer's stockholders.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.